Document is current
Any future updates will be listed below
-
Authors
Tang, Xuming
Xue, Dongxiang
Zhang, Tuo http://orcid.org/0000-0001-5396-918X
Nilsson-Payant, Benjamin E.
Carrau, Lucia http://orcid.org/0000-0003-0260-2841
Duan, Xiaohua
Gordillo, Miriam
Tan, Adrian Y.
Qiu, Yunping
Xiang, Jenny
Schwartz, Robert E. http://orcid.org/0000-0002-5417-5995
tenOever, Benjamin R. http://orcid.org/0000-0003-0324-3078
Evans, Todd http://orcid.org/0000-0002-7148-9849
Chen, Shuibing http://orcid.org/0000-0002-6294-5187
-
Funding
Funding for this research was provided by:
United States Department of Defense | Defense Advanced Research Projects Agency (W911NF-16-C-0050)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK119667, U01 DK127777)
Bill and Melinda Gates Foundation (INV-037420)
- License Information
-
More Information
Article History
Received: 2 May 2022
Accepted: 25 January 2023
First Online: 13 March 2023
Competing interests
: R.E.S. is on the scientific advisory board of Miromatrix Inc, and is a paid consultant and speaker for Alnylam Inc. S.C. and T.E. are the co-founders of OncoBeat, LLC. S.C. is a consultant for Vesalius Therapeutics. The remaining authors declare no competing interests.
